Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica Neurológica, Ambulatório de Medicina do Sono, São Paulo, SP, Brazil.
Universidade de São Paulo, Faculdade de Medicina, Curso de Pós-Graduação, Departamento de Psiquiatria, São Paulo, SP, Brazil.
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):307-312. doi: 10.1590/0004-282X-ANP-2022-S124.
Although, insomnia is one of the most common diseases that health professionals face in their practice, it receives little attention in medical training. Diagnosis is based on a careful history taking, and physicians must be aware of the diagnostic criteria. Insomnia should not be considered a symptom, but a comorbid condition. Although cognitive behavioral therapy (CBT) has been the mainstay treatment for insomnia for many years, it is usually regarded as a novel therapeutic strategy, both because of scarcity of qualified psychologists and of limited knowledge about insomnia among physicians. GABA receptor acting drugs are being abandoned in the treatment of insomnia because of abuse and dependence potential and accident risk. Two main current therapeutic options with the best scientific evidence are the tricyclic antidepressant, doxepin, and a new melatoninergic receptor agonist, ramelteon. Newer drugs to treat insomnia are in the pipeline. Hypocretine blocking agents will be marketed in the near future.
尽管失眠是健康专业人员在实践中最常面临的疾病之一,但在医学培训中却很少受到关注。诊断基于仔细的病史采集,医生必须了解诊断标准。失眠不应被视为一种症状,而是一种共病。尽管认知行为疗法 (CBT) 多年来一直是失眠的主要治疗方法,但由于合格的心理学家稀缺,以及医生对失眠的了解有限,它通常被视为一种新颖的治疗策略。由于滥用和依赖的可能性以及事故风险,GABA 受体作用药物在失眠治疗中被摒弃。目前有两种主要的治疗选择,具有最佳的科学证据,即三环类抗抑郁药多塞平 (doxepin) 和新型褪黑素受体激动剂雷美尔通 (ramelteon)。治疗失眠的新药正在研发中。在不久的将来,食欲素阻断剂将投放市场。